Namita Kundu Selected Research

AH 23848

1/2014	Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties.
9/2009	Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function.
3/2006	Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Namita Kundu Research Topics

Disease

21	Neoplasms (Cancer) 01/2021 - 03/2001
19	Breast Neoplasms (Breast Cancer) 01/2019 - 04/2002
17	Neoplasm Metastasis (Metastasis) 01/2019 - 11/2002
2	Ductal Carcinoma 01/2015 - 01/2014
1	Triple Negative Breast Neoplasms 01/2017

Drug/Important Bio-Agent (IBA)

8	Prostaglandin E Receptors (Prostaglandin E Receptor)IBA 01/2017 - 03/2006
7	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2017 - 03/2006
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 03/2001
4	Chemokine ReceptorsIBA 01/2019 - 08/2006
4	Protein Isoforms (Isoforms)IBA 01/2019 - 04/2002
4	ProstaglandinsIBA 01/2017 - 10/2006
4	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2014 - 04/2002
3	Dinoprostone (PGE2)FDA Link 01/2017 - 02/2012
3	AH 23848IBA 01/2014 - 03/2006
3	Small Interfering RNA (siRNA)IBA 01/2014 - 09/2009
3	frondoside AIBA 01/2014 - 02/2012
3	Prostaglandins EIBA 04/2012 - 03/2006
3	CytokinesIBA 02/2012 - 03/2001
3	Celecoxib (Celebrex)FDA Link 10/2005 - 04/2002
2	InterferonsIBA 01/2019 - 02/2012
2	CXC ChemokinesIBA 01/2019 - 05/2002
2	Indomethacin (Indometacin)FDA LinkGeneric 01/2014 - 10/2005
2	Messenger RNA (mRNA)IBA 10/2010 - 03/2001
2	Interferon-gamma (Interferon, gamma)IBA 09/2009 - 03/2001
2	LigandsIBA 03/2009 - 10/2005
2	Chemotactic FactorsIBA 07/2007 - 05/2002
2	Chemokine CXCL9IBA 07/2007 - 03/2001
2	ChemokinesIBA 08/2006 - 03/2001
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 10/2005 - 04/2002
2	SC 560IBA 11/2002 - 04/2002
2	Interleukin-10 (Interleukin 10)IBA 05/2002 - 03/2001
1	TESIBA 01/2021
1	Immunologic Factors (Immunomodulators)IBA 01/2021
1	15-hydroxyprostaglandin dehydrogenaseIBA 01/2017
1	Phenobarbital (Luminal)FDA Link 01/2017
1	EP4 Subtype Prostaglandin E ReceptorsIBA 01/2014
1	Aldehyde DehydrogenaseIBA 01/2014
1	Adenylyl Cyclases (Adenylyl Cyclase)IBA 01/2013
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2013
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2012
1	Progesterone Receptors (Progesterone Receptor)IBA 02/2012
1	Estrogen ReceptorsIBA 02/2012
1	6-isopropoxy-9-oxoxanthene-2-carboxylic acidIBA 10/2010
1	Hormones (Hormone)IBA 10/2006
1	N- (1- (3- (4- ethoxyphenyl)- 4- oxo- 3,4- dihydropyrido(2,3- d)pyrimidin- 2- yl)ethyl)- N- pyridin- 3- ylmethyl- 2- (4- trifluoromethoxyphenyl)acetamideIBA 08/2006
1	4- (4- cyano- 2- (2- (4- fluoronaphthalen- 1- yl)propionylamino)phenyl)butyric acidIBA 03/2006
1	Therapeutic UsesIBA 10/2005
1	Histocompatibility Antigens Class IIBA 10/2005
1	EnzymesIBA 01/2004
1	hydrogen sulfite (bisulfite)IBA 01/2004
1	Cyclooxygenase 1IBA 11/2002
1	AntibodiesIBA 05/2002
1	Complementary DNA (cDNA)IBA 05/2002
1	InterleukinsIBA 05/2002
1	LipopolysaccharidesIBA 03/2001

Therapy/Procedure

4	Transplantation 01/2014 - 03/2001
2	Oral Administration 01/2013 - 04/2002
1	Therapeutics 01/2021
1	Immunotherapy 07/2007